Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5618709A · kind A · utility
15Cited by
5References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 14, 1994 |
| Grant date | Apr 8, 1997 |
| Priority date | — |
| Expiry date | Jan 14, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/322
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the STK-1 gene. These "antisense" oligonucleotides are hybridizable to the STK-1 mRNA transcript. Such oligonucleotides are useful in treating neoplastic diseases characterized by activation of STK-1 gene expression. The oligonucleotides are also useful as bone marrow purging agents in the treatment of leukemia and metastasized neoplasms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.